К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 6 min

Triple-negative breast cancer: how it is treated today

What triple-negative breast cancer is, why treatment often starts with chemotherapy, when immunotherapy is added and what to do if the cancer has spread.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026

Triple-negative breast cancer is a tumor that has no estrogen or progesterone receptors and no excess of the HER2 protein. That’s why hormone therapy and anti-HER2 drugs don’t work for it, and the basis of treatment remains chemotherapy, to which immunotherapy is now often added. It is an aggressive subtype, but it responds well to drug treatment, especially when given before surgery.

What “triple-negative” means

The breast cancer subtype is determined by immunohistochemistry: ER, PR and HER2. If all three are negative, the tumor is triple-negative. You can check how your results read in the IHC decoder.

According to the American Cancer Society, it accounts for about 10–15% of all breast cancers. It is more common in women before menopause and in carriers of a BRCA1 mutation.

Triple-negative cancer grows faster and comes back more often in the first years than hormone-sensitive tumors. But it has a strength too: it is sensitive to chemotherapy.

Early stages: why treatment often starts with drugs

For small tumors without lymph node involvement, surgery first and then chemotherapy is possible. But for a larger tumor or involved lymph nodes, treatment usually starts with neoadjuvant (pre-surgery) therapy. The American Cancer Society describes it as chemotherapy — alone or together with pembrolizumab (immunotherapy).

This order has an important advantage: after surgery the pathologist sees whether any tumor is left. More on the logic of treatment before and after surgery in the article “Neoadjuvant and adjuvant therapy”.

If tumor remains after chemotherapy

A complete response (no living tumor cells in the removed tissue) is a good prognostic sign. If cells remain, treatment after surgery is stepped up. The American Cancer Society names these options:

  • capecitabine (chemotherapy in tablets) for 18–24 weeks;
  • pembrolizumab after surgery — if it was given before;
  • olaparib for a year — if there is a BRCA mutation.

A year of olaparib may also be considered after surgery without prior chemotherapy — for BRCA carriers with a certain tumor size or lymph node involvement.

Why BRCA testing matters

A BRCA1 mutation is more common in triple-negative cancer than in other subtypes. It affects:

  • the possibility of a PARP inhibitor (olaparib, talazoparib);
  • the choice of chemotherapy for metastatic disease — platinum drugs;
  • testing relatives and prevention for them.

More in the article “BRCA testing: who needs it and why”.

What treatment before surgery is like

Neoadjuvant therapy for triple-negative cancer lasts several months. It is usually a sequence of two stages of chemotherapy with different drugs; if pembrolizumab is part of the regimen, it is given together with the chemotherapy. What to expect:

  • regular blood tests before each infusion — more in the article “Blood tests before a chemotherapy cycle”;
  • monitoring of the response — the doctor assesses the tumor by examination and by ultrasound or MRI midway and at the end of treatment;
  • tests of thyroid and liver function and blood sugar — if immunotherapy is part of the regimen;
  • surgery — usually a few weeks after the last cycle.

If the tumor grows during treatment, the plan is changed — another reason why treatment before surgery is useful: it shows whether the chosen regimen is working.

Metastatic triple-negative breast cancer

For stage 4, the choice of treatment depends on the tumor’s biomarkers. The American Cancer Society describes these situations:

Tumor feature What’s considered
PD-L1-positive (about 1 in 5 tumors) the conjugate sacituzumab govitecan with pembrolizumab, or chemotherapy with pembrolizumab
PD-L1-negative sacituzumab govitecan or datopotamab deruxtecan; standard chemotherapy
BRCA or PALB2 mutation platinum drugs or PARP inhibitors
MSI-H / dMMR or high tumor mutational burden pembrolizumab

Antibody–drug conjugates are antibodies that deliver a chemotherapy drug directly to tumor cells. For triple-negative cancer they have been one of the main changes of recent years.

If you have metastatic triple-negative breast cancer, check whether PD-L1 and BRCA have been tested. Without these results the best first-line treatment can’t be chosen.

How treatment is tolerated

Chemotherapy for triple-negative cancer is usually intensive. The most common problems are a drop in white blood cells, fatigue, nausea, hair loss and numbness in the fingers. Immunotherapy adds the risk of immune-related complications — inflammation of the thyroid, bowel, lungs or skin. More in the article “Side effects of immunotherapy”.

Fertility and pregnancy

Triple-negative cancer is more common in young women, so the question of children comes up often. Chemotherapy can damage the ovaries. If you are planning a pregnancy in the future, discuss fertility preservation before treatment starts — a fertility consultation can be arranged quickly without significantly delaying treatment. If you became pregnant during treatment or are pregnant at diagnosis, tell your oncologist straight away: the approach changes.

How to look after yourself during intensive treatment

  • Don’t skip blood tests — if white cells are low, a cycle may be postponed, and that’s normal.
  • Keep moving — short walks reduce fatigue.
  • Eat when you can — small portions, more protein; more in the article “Nutrition during chemotherapy”.
  • Report symptoms straight away — especially fever, diarrhea, breathlessness, rash.
  • Accept help — intensive treatment is hard to get through alone.

Follow-up after treatment

After treatment ends, follow-up is especially close in the first years — this is when triple-negative cancer more often comes back. The follow-up plan is made by your treating doctor: examinations, mammography or MRI and other tests if needed. If you develop new symptoms that don’t go away (bone pain, cough, headache, weight loss), don’t wait for your scheduled visit. More in the article “Why cancer can come back years later”.

Questions to ask your treating doctor

  • Are we starting with chemotherapy or surgery — and why?
  • Will immunotherapy be part of the regimen?
  • Has BRCA been tested? If not, when will we do it?
  • What will we do if tumor remains after surgery?
  • Which side effects need an immediate call?

If you’ve been diagnosed with triple-negative breast cancer and want to check your plan against current guidelines, I’ll go through your case at a consultation.

Sources

  1. Triple-negative Breast Cancer — American Cancer Society, 2026
  2. Treatment of Triple-negative Breast Cancer — American Cancer Society, 2026
  3. Pembrolizumab — National Cancer Institute

Watch me explain this on video

Short videos on my Instagram (in Russian)

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.